Upcoming event
23rd Meeting of the EAU Robotic Urology Section
Back

Tag: ASCO2026

Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab for participants with muscle-invasive bladder cancer who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study

Urinary tumor DNA–guided de-escalation of systemic immunotherapy in extensive very high risk non–muscle-invasive bladder cancer

Rethinking the role of tumor size in bladder preservation: Comparing survival outcomes of radical cystectomy (RC) and tri-modality therapy (TMT)